New Project ARTEMIs
The ARTEMIs project aims to consolidate existing computational mechanistic and machine-learning models at different scales to deliver ‘virtual twins’ embedded in a clinical decision support system (CDSS).
The CDSS will provide clinically meaningful information to clinicians for a more personalised management of the whole spectrum of Metabolic Associated Fatty Liver Disease (MAFLD). MAFLD, with an estimated prevalence of about 25%, goes from an undetected sleeping disease to inflammation (hepatitis), to fibrosis development (cirrhosis) and/or hepatocellular carcinoma (HCC), decompensated cirrhosis and HCC being the final stages of the disease. However, many MAFLD patients do not die from the liver disease itself but from cardiovascular comorbidities or complications. The project will contribute to the earlier management of MAFLD patients by prognosing the development of more advanced forms of the disease and cardiovascular comorbidities and promoting active surveillance of patients at risk. The system will predict the impact of novel drug treatments, procedures, or better life habits. The system will, therefore, serve as a clinical decision-aid tool and an educational tool for patients to promote better nutritional and lifestyle behaviours. In more advanced forms of the disease, therapeutic interventions include TIPS (Transjugular intrahepatic portosystemic shunt) to manage portal hypertension, partial hepatectomy, and partial or complete liver transplant. ARTEMIs will contribute to predicting pre – or post-intervention heart failure, building on existing microcirculation hemodynamics models. The model developers will benefit from a large distributed patient cohort and data exploration environment to identify patterns in data, draw new theories on the liver-heart metabolic axis and validate the performance of their models. The project includes a proof-of-concept feasibility study assessing the utility of the integrated virtual twins and CDSS in the clinical context.